BioMarin Pharmaceutical/ US09061G1013 /
8/9/2022 9:59:59 PM | Chg. +0.01 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
95.70USD | +0.01% | 54,239 Turnover: 5.22 mill. |
-Bid Size: - | -Ask Size: - | 17.75 bill.USD | 0.00% | - |
Assets
2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Property and Equipment | 284.5000 | 319.3000 | 523.5000 | 704.2000 | 798.8000 | ||||||
Intangible Assets | 163 | 163.1000 | 156.6000 | 684 | 553.8000 | ||||||
Long-Term Investments | - | - | - | - | - | ||||||
Fixed Assets | - | - | - | - | - | ||||||
Inventories | 128.7000 | 162.6000 | 199.5000 | 271.7000 | 355.1000 | ||||||
Accounts Receivable | - | - | - | - | - | ||||||
Cash and Cash Equivalents | 180.5000 | 568.8000 | 875.5000 | 397 | 408.3000 | ||||||
Current Assets | 743.5000 | 1,137.4000 | 1,425.6000 | 1,089.6000 | 1,421.8000 | ||||||
Total Assets | 1,601.6000 | 2,249.2000 | 2,490.5000 | 3,729.4000 | 4,023.7000 |
Liabilities
2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Accounts Payable | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
Long-term debt | - | - | - | - | - | ||||||
Liabilities to Banks | 23.4000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
Provisions | 33.3000 | - | - | 143.5000 | - | ||||||
Liabilities | 585.9000 | 908.2000 | 962.6000 | 1,328.5000 | 1,257.4000 | ||||||
Share Capital | - | - | - | - | - | ||||||
Total Equity | 1,015.8000 | 1,341 | 1,527.9000 | 2,400.8000 | 2,766.3000 | ||||||
Minority Interests | - | - | - | - | - | ||||||
Total liabilities equity | 1,601.6000 | 2,249.2000 | 2,490.5000 | 3,729.4000 | 4,023.7000 |
Income Statement
2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 500.7000 | 548.5000 | 751 | 889.9000 | 1,116.9000 | ||||||
Depreciation (total) | 18.7000 | 18.6000 | 18 | -17.7000 | -27 | ||||||
Operating Result | -110.2000 | -156 | -92.9000 | -110.7000 | -803.4000 | ||||||
Interest Income | -5 | -7.3000 | -30.7000 | -33.7000 | -32 | ||||||
Income Before Taxes | -118.3000 | -176.5000 | -124.9000 | -154.7000 | -831.1000 | ||||||
Income Taxes | -3.9000 | -.2000 | 9.1000 | 17.1000 | -200.8000 | ||||||
Minority Interests Profit | - | - | - | - | - | ||||||
Net Income | -114.3000 | -176.4000 | -134 | -171.8000 | -630.2000 |
Per Share
Cash Flow
2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Cash Flow from Operating Activities | 17.6000 | -59.6000 | -73.5000 | -221.7000 | -227.8000 | ||||||
Cash Flow from Investing Activities | -195.6000 | -298.8000 | 194.6000 | -1,179.6000 | -484 | ||||||
Cash Flow from Financing | 312.3000 | 746.7000 | 185.7000 | 927.9000 | 727.1000 | ||||||
Decrease / Increase in Cash | 134.3000 | 388.3000 | 306.7000 | -478.4000 | 11.3000 | ||||||
Employees | 1,089 | 1,341 | 1,681 | 2,158 | 2,293 |